Tarsus Pharmaceuticals (TARS) Accumulated Depreciation & Amortization (2020 - 2025)
Historic Accumulated Depreciation & Amortization for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $460000.0.
- Tarsus Pharmaceuticals' Accumulated Depreciation & Amortization rose 6197.18% to $460000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $460000.0, marking a year-over-year increase of 6197.18%. This contributed to the annual value of $1.2 million for FY2024, which is 3968.07% up from last year.
- According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Accumulated Depreciation & Amortization is $460000.0, which was up 6197.18% from $453000.0 recorded in Q2 2025.
- Tarsus Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $1.2 million for Q4 2024, and its period low was $142000.0 during Q1 2021.
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $354000.0 (2022), whereas its average is $482105.3.
- As far as peak fluctuations go, Tarsus Pharmaceuticals' Accumulated Depreciation & Amortization soared by 27634.41% in 2021, and later crashed by 7274.47% in 2024.
- Tarsus Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $221000.0 in 2021, then surged by 47.51% to $326000.0 in 2022, then surged by 169.02% to $877000.0 in 2023, then skyrocketed by 39.68% to $1.2 million in 2024, then crashed by 62.45% to $460000.0 in 2025.
- Its Accumulated Depreciation & Amortization was $460000.0 in Q3 2025, compared to $453000.0 in Q2 2025 and $460000.0 in Q1 2025.